Loading patent…
AssigneesDeutsches Krebsforschungszentrum, Ruprecht-Karls-Universitaet Heidelberg
InventorsJean Rommelaere, Zahari Raykov, Joerg Schlehofer, Irina Kiprijanova, Tanja Heimberger, Assia Angelova, Karsten Geletneky, Marc Aprahamian
Estimating the term…
Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.
A method for the treatment of cancer comprising administering to a patient in need thereof an effective amount of (a) parvovirus and (b) a chemotherapeutic agent,
A method for the treatment of pancreatic cancer comprising administering to a patient in need thereof a parvovirus H1 (HIPV) or a related rodent parvovirus selected from the group consisting of LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV) or Rat virus (RV).
Dependencies are inferred from the claim text.